Reduced relapse rates and induction of tumor-specific immune responses by adjuvant immunotherapy in stage IV melanoma;Verminderte progressionsrate und induktion tumorspezifischer immunantworten durch adjuvante immuntherapie bei stadium-IV-melanomen

Hautarzt

Volumn 50, Issue 2, 1999, Pages 103-108

  Enk, Alexander H ^a   Wölfel, Thomas ^a   Knop, Jürgen ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Interferon; Interleukin 2; Melanoma; Stage IV

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; DACARBAZINE; INTERLEUKIN 2; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MALE; MELANOMA; PROGNOSIS; RECURRENCE RISK; RELAPSE; TREATMENT OUTCOME;

ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0345390879     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001050050872     Document Type: Article

References (12)

1. Blum A, Ellwanger U, Garbe C (1996) Das Maligne Melanom der Haut. Analyse der Daten des Zentralregisters Malignes Melanom der Deutschen Dermatologischen Gesellschaft, 1983-1995. Krebsverband Baden Württemberg
2. Anderson CM, Buzaid AC, Legha S (1995) Systemic treatments for advanced cutaneous melanoma. Oncology 9:1149-1185
3. Balch CM, Houghton AN, Milton GW, Soong SJ (1998) Cutaneous melanoma. Lippincott, Philadelphia
4. Lakhani S, Selby P, Bliss JM, Perren TJ, Gore ME, McElwainTJ (1990) Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. Br J Cancer 61:330-334
5. Garbe C, Kreuser ED, Zoubolis CC, Stadler R, Orfanos E (1992) Combined treatment of metastatic melanoma with interferons and cytotoxic drugs. Semin Oncol 19:63-69
6. Kirkwood JM (1991) Studies of interferons in the therapy of melanoma. Semin Oncol 18:83-90
7. Rosenberg SA, Yang JC, Topalian SL (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose bolus interleukin-2. JAMA 271:907-913
8. Hauschild A, Dummer C, Garbe C, Kaufmann R, Schadendorf D, Soyer HP, Stadler R, Tilgen W (1998) Adjuvante Interferon-α-Therapie beim Melanom. Hautarzt 49:167-169
9. Oliver RTD, Nouri AME (1991) T cell immune response to cancer in humane and its relevance for immunodiagnosis and therapy. Cancer Surv 13:173-176
10. Burnet FM (1970) The concept of immune surveillance. Proc Exp Tumor Res 13:1-12
11. Birchmeier W, Weidner K, Hulsken J, Behrens J (1993) Molecular mechanisms leading to loss of differentiation and gain of invasiveness in tumor cells. J Cell Sci 17:159-164
12. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-346